# What 49 Preclinical Studies Suggest About Cannabis and Redox Biology > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-oxidative-stress/ > **Published:** 2026-04-17T21:47:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T15:56:43-04:00 > **Clinical Summary:** Cannabis oxidative stress findings in cells and animals suggest possible biologic effects, but this preclinical review does not prove harm in humans --- By **Dr. Benjamin Caplan, MD**  |  Board-Certified Family Physician, CMO at CED Clinic  |  Evidence Watch Clinical Insight | CED Clinic A 2026 systematic review of 49 preclinical studies found that cannabis and cannabinoid compounds are associated with increased oxidative stress markers and depleted antioxidant defenses in animal and cell models. However, effect sizes were highly variable, the in vitro findings were negligibly small, and no human data were included, meaning these results cannot be directly translated into clinical conclusions about cannabis harm. ## Lab Studies Suggest Cannabis Exposure Alters Oxidative Stress Markers, But Human Relevance Remains Unproven A systematic review and meta-analysis of 51 preclinical studies finds cannabinoid exposure associated with increased reactive oxygen species production and antioxidant enzyme changes in cells and animals, with highly variable effect sizes that underscore the persistent gap between preclinical observation and clinical certainty. CED Clinical Relevance #48 Moderate Relevance Provides mechanistic groundwork for future human studies on cannabinoid-induced oxidative stress, but no direct clinical applicability at this time. Oxidative Stress Cannabis Toxicology Preclinical Research Systematic Review CBD & THC Why This Matters Cannabis is the most widely used psychoactive substance worldwide, and understanding its potential mechanisms of cellular harm is essential for informing regulatory toxicology, clinical monitoring, and patient counseling. Oxidative stress, the imbalance between reactive oxygen species and the body’s antioxidant defenses, is implicated in neurodegenerative disease, cardiovascular damage, and accelerated aging. If cannabinoid exposure systematically disrupts redox balance, that pathway would need to be considered in safety evaluations for millions of current users. This review represents the first large-scale quantitative synthesis of preclinical evidence on that question, making it a critical waypoint for research prioritization even if its findings cannot yet cross the bridge from laboratory bench to bedside. Study at a Glance Study Type Systematic review and meta-analysis (preclinical only) Population Cell lines (23 in vitro studies) and animals (26 in vivo studies; 1,258 animals, primarily rats and mice) Intervention / Focus Cannabis and cannabinoid exposure: THC, CBD, THC+CBD combinations, crude extracts, and synthetic cannabinoids Comparator Untreated or vehicle control groups within individual primary studies Primary Outcomes ROS production, lipid peroxidation (MDA/TBARS), antioxidant enzyme activity (SOD, CAT, GPx, GR), glutathione (GSH), total antioxidant/oxidant capacity Sample Size 9,775 records screened; 51 studies included (49 quantitatively analyzed) Journal Regulatory Toxicology and Pharmacology Year 2026 DOI / PMID 10.1016/j.yrtph.2026.106067 / PROSPERO CRD420251020006 Funding Source Not explicitly reported Clinical Summary Oxidative stress, the biological imbalance between reactive oxygen species and the body’s capacity to neutralize them through antioxidant enzymes, has been implicated as a potential mechanism through which [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) might contribute to cellular damage. Despite widespread [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) globally, no prior systematic review had quantitatively pooled preclinical biomarker data across multiple cannabinoid types and biological systems. This 2026 meta-analysis searched six databases over a ten-year window, screening 9,775 records and including 49 studies for quantitative synthesis, spanning cell lines and animal models exposed to THC, CBD, combined formulations, crude extracts, and synthetic cannabinoids. In animal studies, cannabinoid exposure was associated with a moderate increase in reactive oxygen species (standardized mean difference of 0.93, with a 95% confidence interval from 0.10 to 1.75), increased lipid peroxidation, and reduced superoxide dismutase and glutathione peroxidase activity. In cell studies, the ROS increase was statistically significant but negligibly small (SMD of 0.04), though decreases in glutathione, glutathione reductase, and catalase were more consistent. Heterogeneity across studies was substantial, driven by differences in cannabinoid type, species, dose, and route of administration. The authors explicitly acknowledged that findings suggest a “possible biological pathway” rather than definitive evidence of a consistent effect, and that human translational studies remain essential before any clinical or regulatory conclusions can be drawn. Dr. Caplan’s Analysis A physician’s reading of the evidence ### Cannabis and Oxidative Stress: What 49 Preclinical Studies Actually Show A new systematic review synthesizes fifty years’ worth of cannabis biochemistry into a single finding: in cells and animals, cannabis disrupts the body’s antioxidant defenses. But the leap from a rat’s liver enzymes to a human patient’s health risk remains one of medicine’s most stubborn translation problems. The paper claims to demonstrate that cannabinoid exposure shifts oxidative stress biomarkers in preclinical models, and on its own terms, it largely succeeds. The multi-biomarker, dual-system approach is genuinely novel, and the authors deserve credit for maintaining restrained language throughout, explicitly refusing to overstate what their data can and cannot show. The consistent pattern of antioxidant enzyme depletion across both in vitro and in vivo models, including reduced glutathione, catalase, superoxide dismutase, and glutathione peroxidase, is the review’s most coherent contribution. It suggests a mechanistically plausible pathway worth studying in humans. That said, the central methodological issue here is one of selective framing. The review explicitly excluded studies focused on the antioxidant effects of cannabis. Think of it this way: it is like studying the fatigue effects of coffee by only including studies where subjects stayed awake too long, while excluding all studies showing coffee improves alertness. You will confirm what you set out to find. CBD, which has well-documented antioxidant and neuroprotective properties in other contexts, appears here only through the lens of its pro-oxidant potential. This asymmetry is acknowledged but insufficiently addressed, and it limits the review’s ability to characterize the net oxidative impact of cannabinoid exposure, which is the question most relevant to real-world health. The divergence between in vitro and in vivo effect sizes is also telling. The in vitro ROS finding, an SMD of 0.04, is the statistical equivalent of measuring the height of a million people and detecting a one-millimeter difference between groups: technically significant, biologically meaningless. The in vivo estimate is more substantial, but its confidence interval spans from 0.10 to 1.75, reflecting enormous variability across species, doses, and experimental conditions. Pooling THC, CBD, and synthetic cannabinoids into a single estimate obscures the fact that these compounds have distinct pharmacological profiles. Synthetic cannabinoids, in particular, are known to produce far more aggressive cellular effects than phytocannabinoids, and lumping them together risks inflating the apparent hazard of plant-derived cannabis products. No dose-response modeling was attempted, so we cannot determine whether the doses used in these animal studies have any overlap with typical human exposure levels. If a patient asked me whether this review means cannabis is damaging their cells, I would say: there is laboratory evidence that cannabinoid compounds can increase oxidative stress markers in animals and cell cultures, but we do not yet have good human studies showing this translates into meaningful health consequences at typical use levels. What we do know is that heavy use, particularly of high-THC products or synthetic cannabinoids, carries real risks worth discussing. To a colleague, I would highlight this as a well-executed preclinical synthesis that identifies antioxidant depletion as a priority biomarker for human pharmacovigilance studies, while cautioning that the in vitro ROS finding is trivially small and that CBD’s antioxidant profile is systematically underrepresented. To a policymaker, I would advise using these data to inform biomarker selection for human safety monitoring, not to characterize cannabis harm in regulatory documents. Statistically significant pooled preclinical findings, even from rigorous systematic reviews, occupy a specific and limited epistemic tier. They establish mechanistic plausibility and identify research priorities, but they cannot substitute for human evidence when evaluating real-world health risk. Clinical Perspective This review occupies a specific position in the research arc: it is a hypothesis-generating preclinical synthesis, not a clinical evidence base. For practitioners managing cannabis-using patients, it provides no actionable data on dosing thresholds, duration of exposure, or clinical outcomes. Its principal value lies in identifying which biomarkers, specifically SOD, GPx, GSH, and MDA, deserve priority measurement in future human pharmacovigilance and cohort studies. It also clarifies that the oxidative stress question remains open, not settled, despite the volume of preclinical work accumulated over the past decade. From a pharmacological standpoint, the review’s inclusion of synthetic cannabinoids alongside THC and CBD is important context for clinicians, because synthetic cannabinoid toxicity profiles are substantially more severe than those of plant-derived products. Clinicians should remain aware that oxidative stress pathways represent a biologically plausible concern, particularly for patients using high-dose THC products or synthetic formulations, but should not counsel patients that cannabis has been shown to cause oxidative harm in humans. The one concrete action warranted by this review is for clinicians involved in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) or monitoring to advocate for the inclusion of antioxidant enzyme panels in prospective [cannabis safety studies](https://cedclinic.com/cannabis-brain-activation-study-effects-memory/). What Kind of Evidence Is This This is a PRISMA-compliant systematic review with meta-analysis, pre-registered on PROSPERO, restricted entirely to preclinical studies conducted in cell lines and animal models. Within the evidence hierarchy, it sits above individual preclinical experiments but below even observational human studies, because no amount of methodological rigor in pooling animal data can overcome the fundamental translational barrier between non-human systems and human health outcomes. The single most important constraint on inference is that these findings cannot be extrapolated to clinical risk in cannabis users without bridging human biomarker evidence that does not yet exist. How This Fits With the Broader Literature This review extends the preclinical oxidative stress literature by providing the first pooled quantitative estimates across multiple biomarker classes and dual biological systems. It is broadly consistent with the mechanistic concerns raised in individual primary studies but adds the important nuance that effect sizes are highly heterogeneous and in vitro findings are negligibly small. It complements the clinical meta-analysis by Bilbao and Spanagel (2022), which examined therapeutic cannabinoid applications across medical indications, and the psychiatric symptom meta-analysis by Hindley and colleagues (2020), both of which operated at the human evidence level that this review cannot reach. Taken together, the literature confirms that the oxidative stress hypothesis for cannabis harm remains biologically plausible but empirically unresolved in humans. Could Different Analyses Have Changed the Result? The most consequential analytic choice was pooling all cannabinoid types, including THC, CBD, crude extracts, and synthetic cannabinoids, into single meta-analytic estimates. Stratifying by compound class would almost certainly have produced different results, particularly by separating the likely more toxic synthetic cannabinoids from phytocannabinoids. Had the review also included studies examining CBD’s antioxidant properties rather than excluding them by design, the net oxidative balance estimates could have shifted substantially, potentially revealing that certain cannabinoid profiles have net protective or neutral effects. The absence of dose-response modeling is also significant; including dose as a covariate in meta-regression would have provided critical context about whether the exposure levels studied in animals approximate real-world human consumption patterns. Common Misreadings The most likely overinterpretation is that this review proves cannabis causes oxidative damage in humans. It does not. All data derive from cell lines and animals, and no human outcomes were measured or synthesized. A related misreading involves the in vitro ROS finding: an SMD of 0.04, while statistically significant, represents a negligible effect size driven by large sample volumes rather than biologically meaningful change. It would also be incorrect to conclude that CBD is inherently pro-oxidant based on this review, because the study design explicitly excluded research demonstrating CBD’s well-documented antioxidant properties, creating an asymmetric evidence base that cannot characterize CBD’s net redox profile. Bottom Line This review contributes the most comprehensive quantitative synthesis of preclinical cannabinoid oxidative stress data to date, identifying a consistent pattern of antioxidant defense impairment across animal and cell models. It does not establish that cannabis causes oxidative harm in humans, nor does it provide dose-response data relevant to typical use. For clinical practice, the findings warrant no immediate changes but strongly support prioritizing human biomarker studies measuring antioxidant enzymes and lipid peroxidation in cannabis users. Frequently Asked Questions Does this study prove that cannabis causes cell damage in people? No. All of the data in this review come from experiments on cells in dishes and on laboratory animals. No human data were included. The findings suggest a biological mechanism worth investigating in people, but they do not establish that cannabis causes oxidative damage in human users at any dose. Does this mean CBD is harmful? This review cannot answer that question. Its design deliberately excluded studies examining CBD’s antioxidant and protective properties, so it captures only one side of CBD’s complex biological profile. Other research has documented significant antioxidant and neuroprotective effects of CBD in certain contexts. The picture is nuanced and context-dependent. Should I stop using cannabis based on this review? This preclinical review does not provide sufficient evidence to change any individual’s [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) decisions. If you have concerns about cannabis and your health, the best course of action is to discuss your specific situation, including product type, dose, and medical history, with a knowledgeable physician who can provide personalized guidance. What are oxidative stress biomarkers, and why do they matter? Oxidative stress biomarkers are measurable substances in cells and tissues that indicate whether the body’s balance between damaging reactive oxygen species and protective antioxidant defenses has been disrupted. Chronic oxidative stress imbalance is associated with aging, neurodegeneration, and cardiovascular disease. This review found that cannabinoid exposure in lab settings was associated with changes in several of these markers, but whether those changes reach levels that matter for human health is still unknown. What kinds of studies were included in this oxidative stress review? The review included 51 preclinical studies, with 49 analyzed quantitatively. These were 23 cell line studies and 26 animal studies involving 1,258 animals, mostly rats and mice. Exposures included THC, CBD, THC and CBD combinations, crude extracts, and synthetic cannabinoids, compared with untreated or vehicle control groups. No human data were included. Were the oxidative stress effects larger in animal studies or cell studies? They were larger in animals. In animal studies, cannabinoid exposure was linked to a moderate rise in reactive oxygen species (SMD 0.93, 95% confidence interval 0.10 to 1.75), more lipid peroxidation, and lower superoxide dismutase and glutathione peroxidase activity. In cell studies, the rise was statistically significant but negligibly small (SMD 0.04), though drops in glutathione, glutathione reductase, and catalase were more consistent. Why does pooling THC, CBD, and synthetic cannabinoids together matter here? It matters because results may differ by compound type. The review combined THC, CBD, crude extracts, and synthetic cannabinoids into single pooled estimates. According to the article, separating results by compound class would almost certainly have changed the findings, particularly by setting apart the likely more toxic synthetic cannabinoids from plant-derived cannabinoids. Heterogeneity across studies was substantial, partly because of differences in cannabinoid type. Does this review show whether typical human doses cause oxidative stress? No. The review did not attempt dose-response modeling, so it cannot say whether the doses used in animal studies resemble real-world human consumption. The article states that the review does not establish that cannabis causes oxidative harm in humans and does not provide dose-response data relevant to typical use. **References** - Sanz-Perez A, Perez T, Gonzalez-Burgos E. Preclinical evidence of cannabis-induced oxidative stress: A systematic review and meta-analysis. *Regulatory Toxicology and Pharmacology*. 2026;168:106067. doi:10.1016/j.yrtph.2026.106067 - Sies H. Oxidative stress: a concept in redox biology and medicine. *Redox Biology*. 2015. - Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. *BMC [Medical Research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) Methodology*. 2014;14:43. - Schneider K, Schwarz M, Burkholder I, et al. ToxRTool, a new tool to assess the reliability of toxicological data. *Toxicology Letters*. 2009;189(2):138-144. - Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. - Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. *BMC Medicine*. 2022. - Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. *The Lancet Psychiatry*. 2020. - Ludecke D. esc: Effect Size Computation for Meta Analyses. R package. 2022. Further Reading Evidence WatchCannabis Safety: What the Evidence Actually Shows CED Clinic BlogCBD and Antioxidant Properties: What We Know Evidence WatchUnderstanding Preclinical vs. Clinical Evidence in [Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabis+and+Oxidative+Stress%3A+What+Preclinical+Studies+Really+Show&url=https%3A//cedclinic.com/cannabis-oxidative-stress/) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//cedclinic.com/cannabis-oxidative-stress/) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Cannabis+and+Oxidative+Stress%3A+What+Preclinical+Studies+Really+Show+https%3A//cedclinic.com/cannabis-oxidative-stress/) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/evidence-watch/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).